Vir Biotechnology, Inc.

NasdaqGS:VIR Stock Report

Market Cap: US$1.0b

Vir Biotechnology Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:VIR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Dec 24SellUS$625Vanina de VerneuilIndividual76US$8.22
01 Nov 24SellUS$10,107Vanina de VerneuilIndividual1,403US$7.20
11 Jun 24SellUS$43,789Sona Saira RamasastryIndividual4,000US$10.95
03 Apr 24SellUS$690,365Marianne De BackerIndividual72,995US$9.46
01 Apr 24SellUS$27,251Ann HanlyIndividual2,711US$10.05
27 Mar 24SellUS$59,404Sung LeeIndividual6,008US$9.89
22 Feb 24SellUS$100,737George ScangosIndividual10,028US$10.05
22 Feb 24SellUS$146,344Phillip PangIndividual14,568US$10.05
22 Feb 24SellUS$123,521Ann HanlyIndividual12,296US$10.05
16 Feb 24SellUS$34,006Phillip PangIndividual3,321US$10.24
16 Feb 24SellUS$111,386George ScangosIndividual10,878US$10.24

Insider Trading Volume

Insider Buying: VIR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of VIR?
Owner TypeNumber of SharesOwnership Percentage
Private Companies10,0000.00726%
State or Government38,0410.0276%
Individual Insiders7,004,4315.09%
Public Companies8,550,9546.21%
General Public20,507,18014.9%
VC/PE Firms29,600,70421.5%
Institutions72,008,81052.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.

Top Shareholders

Top 25 shareholders own 72.91% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.1%
SB Investment Advisers (UK) Limited
16,684,041US$122.5m0%0.65%
11.9%
BlackRock, Inc.
16,375,806US$120.2m-0.35%no data
9.54%
The Vanguard Group, Inc.
13,135,956US$96.4m2.23%no data
9.38%
Arch Venture Partners, L.P.
12,916,663US$94.8m0%9.86%
6.21%
GSK plc
8,550,954US$62.8m0%no data
4.08%
State Street Global Advisors, Inc.
5,625,533US$41.3m10.4%no data
2.78%
George Scangos
3,834,548US$28.1m0.21%no data
2.59%
OrbiMed Advisors LLC
3,573,000US$26.2m54%0.38%
1.73%
Baillie Gifford & Co.
2,383,029US$17.5m-39.2%0.01%
1.59%
Geode Capital Management, LLC
2,188,774US$16.1m0.24%no data
1.13%
Bill & Melinda Gates Foundation Trust
1,559,142US$11.4m0%0.03%
0.96%
Vicki Sato
1,323,351US$9.7m0%no data
0.88%
Dimensional Fund Advisors LP
1,212,105US$8.9m90.1%no data
0.86%
Renaissance Technologies LLC
1,182,300US$8.7m-11.1%0.01%
0.82%
Charles Schwab Investment Management, Inc.
1,134,276US$8.3m13.6%no data
0.8%
Millennium Management LLC
1,104,716US$8.1m-11.5%0.01%
0.79%
Jefferies Financial Group Inc.,Asset Management Arm
1,085,210US$8.0m0%0.13%
0.71%
JP Morgan Asset Management
981,807US$7.2m6.09%no data
0.71%
Voloridge Investment Management, LLC
975,300US$7.2m-20.4%0.03%
0.68%
D. E. Shaw & Co., L.P.
930,655US$6.8m0.88%0.01%
0.64%
Northern Trust Global Investments
878,924US$6.5m5.45%no data
0.55%
Morgan Stanley, Investment Banking and Brokerage Investments
755,349US$5.5m-48.8%no data
0.52%
Goldman Sachs Group, Investment Banking and Securities Investments
721,971US$5.3m56.5%no data
0.48%
Bridgeway Capital Management, LLC
659,562US$4.8m-48.6%0.08%
0.47%
BNY Asset Management
642,283US$4.7m-21%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Huidong WangBarclays
Alec StranahanBofA Global Research